Theravia

Theravia is a French laboratory developing medical products for the treatment of rare diseases, created from the merger of two of our portfolio companies, CTRS and Addmedica.

Addmedica was a European-based privately owned specialty pharma company focused on developing and marketing medical products for rare diseases and niche markets. By developing, registering and/or marketing dedicated medical products (medicinal products, medical devices or diagnosis) for rare and debilitating diseases, the mission of Addmedica was to provide physicians, patients and managed care organizations with high medical value solutions.
The company’s growth was driven by an original business model - including partnerships that are specifically adapted to the development, marketing and distribution of innovative and original products dedicated to rare diseases, serious conditions and unmet medical needs.

Laboratoires CTRS (Cell Therapies Research & Services), was a French pharmaceutical company focused on developing and marketing drugs for rare diseases and with a strong and growing international presence. Its main areas of expertise are Hereditary metabolic diseases and Oncology-haematology-immunology.
CTRS has developed a smart and efficient business model thanks to its ability to secure strategic partnerships (strong and long-lasting relationship with AP-HP) combined with the ability to detect unmet needs (network of KOLs, management and doctors) and a smart regulatory strategy.